project id: TCGA-UVM; case submitter id: TCGA-VD-A8KH; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.89; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.55; rna integrity number: 8.6; age at index: 69; days to birth: -25388; ethnicity: not reported; gender: male; race: not reported; vital status: Alive; year of birth: 1943; age at diagnosis: 25388; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage IIIB; ajcc clinical t: T4b; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage IIIB; ajcc pathologic t: T4b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1158.0; icd 10 code: C69.80; last known disease status: not reported; morphology: 8770/3; primary diagnosis: Mixed epithelioid and spindle cell melanoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Overlapping lesion of eye and adnexa; synchronous malignancy: No; tissue or organ of origin: Overlapping lesion of eye and adnexa; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 497; days to sample procurement: 0; initial weight: 70.0; portion submitter id: TCGA-VD-A8KH-01A-11; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 80.0;